Protagonist Therapeutics Inc [PTGX] stock prices are up 2.28% to $46.61 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The PTGX shares have gain 5.29% over the last week, with a monthly amount glided 1.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on December 06, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $47. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $62. On November 05, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $58 on the stock. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $65 on September 24, 2024. Truist initiated its recommendation with a Buy and recommended $60 as its price target on September 09, 2024. CapitalOne started tracking with a Overweight rating for this stock on October 30, 2023, and assigned it a price target of $32.
The stock price of Protagonist Therapeutics Inc [PTGX] has been fluctuating between $27.00 and $60.60 over the past year. Currently, Wall Street analysts expect the stock to reach $70.25 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $46.61 at the most recent close of the market. An investor can expect a potential return of 50.72% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
The Protagonist Therapeutics Inc [NASDAQ:PTGX] reported sales of 207.80M for trailing twelve months, representing a drop of -88.89%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.27%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.09 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Protagonist Therapeutics Inc [NASDAQ:PTGX]’s Current Ratio is 17.26. On the other hand, the Quick Ratio is 17.26, and the Cash Ratio is 3.98. Considering the valuation of this stock, the price to sales ratio is 13.90, the price to book ratio is 4.19 and price to earnings (TTM) ratio is 61.27.
Transactions by insiders
Recent insider trading involved Ali Asif, Chief Financial Officer, that happened on Apr 22 ’25 when 1756.0 shares were sold. Director, Waddill William D. completed a deal on Mar 17 ’25 to sell 4000.0 shares. Meanwhile, Director WILLIAM D WADDILL bought 4000.0 shares on Mar 17 ’25.
